LA
HALO icon

Lindenwold Advisors’s Halozyme HALO Stock Holding History

Lindenwold Advisors’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$603K Buy
8,221
+201
+3% +$13.4K 0.28% 66
2025
Q2 		$417K Buy
8,020
+50
+0.6% +$2.85K 0.22% 72
2025
Q1 		$509K Buy
7,970
+2,970
+59% +$173K 0.28% 63
2024
Q4 		$239K Buy
+5,000
New +$256K 0.13% 105

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Lindenwold Advisors's HALO Position: Q3 2025 in Review

Lindenwold Advisors increased its Halozyme (HALO) stake by 2.5% in Q3 2025, buying an estimated $13.4K and bringing the position to 8,221 shares worth $603K. The position accounts for 0.28% of the portfolio, ranked #66.

Lindenwold Advisors first reported a position in HALO in Q4 2024 and has held it in 4 quarters since. 602 funds tracked by Wall St. Rank hold HALO as of Q3 2025.

  • Lindenwold Advisors held 8,221 shares of Halozyme worth $603K as of Q3 2025.
  • Lindenwold Advisors bought 201 Halozyme shares in Q3 2025, an estimated $13.4K.
  • Halozyme made up 0.28% of Lindenwold Advisors's portfolio in Q3 2025, its #66 holding.
  • Lindenwold Advisors first reported a position in Halozyme in Q4 2024 and has held it in 4 quarters since.
  • 602 funds tracked by Wall St. Rank held Halozyme as of Q3 2025.

Based on Lindenwold Advisors's 13F filing for Q3 2025, filed 16 Dec 2025.